Results 151 to 160 of about 3,020 (210)

Melioidosis in companion animals: Analysis of 45 Australian cases (24 dogs; 21 cats) from 1997 to 2025 and a brief review of the animal and human literature

Australian Veterinary Journal, EarlyView.
Objective To report 45 cases of melioidosis in dogs and cats from northern Australia and analyse trends in epidemiology, clinical presentation, pathogenesis and response to treatment over a 27‐year period. Design Retrospective and prospective analysis of clinical records.
K Lee, C Shilton, S Benedict, M Krockenberger, M Mayo, BJ Currie, R Malik   +6 more
wiley   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber, Mélusine Humbert‐Droz, Laura Ley, Yasmin Schmid, Matthias E. Liechti   +4 more
wiley   +1 more source

Identification of predictive factors for reversal of cerebral vasculopathy in an original longitudinal cohort study in newborns with sickle cell anaemia

British Journal of Haematology, EarlyView.
Summary Cerebral macrovasculopathy (CV) is a major complication in children with sickle cell anaemia (SCA) and usually requires a long‐term transfusion programme (TP) to prevent stroke. This study aimed to identify factors predicting reversal of CV on TP in a single‐centre newborn cohort. Among 375 patients, 50 presented CV and received TP.
Julie Sommet, Priscilla Boizeau, Zinedine Haouari, Berengère Koehl, Monique Elmaleh, Emmanuelle Lesprit, Florence Missud, Ghislaine Ithier, Laurent Holvoet, Valentine Brousse, Christophe Delclaux, André Denjean, Suzanne Verlhac, Corinne Alberti, André Baruchel, Nathalie Couque, Malika Benkerrou   +16 more
wiley   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

British Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend, Nilanjan Ghosh, Martin Hutchings, Michael Dickinson, Monica Tani, Armando Santoro, Michael Crump, Amitkumar Mehta, Reinhard Marks, Martin Weisser, Martin Barrett, Chun Wu, Derrick Kaufman, Katharina Lechner, Pauline Baumlin, Pontus Lundberg, Max S. Topp   +16 more
wiley   +1 more source

Peritoneal Cystic Lymphangioma Mimicking a Femoral Hernia

ANZ Journal of Surgery, EarlyView.
Imen Ben Ismail, Marwen Sghaier, Saber Rebii, Hakim Zenaidi, Ayoub Zoghlami   +4 more
wiley   +1 more source

Human brain matters: Navigating the neuropathology of COVID‐19

Brain Pathology, EarlyView.
Severe COVID‐19 is associated with vascular dysregulation and chronic neuroinflammation, leading to axonal injury and neurodegeneration. In long COVID or PASC, persistent alterations in neuroimaging and biofluid biomarkers reflect ongoing neuronal damage and neuroinflammation, contributing to long‐term neurological symptoms including fatigue, cognitive
Juliana M. Nieuwland, Angelica Scaramuzza, Marianna Bugiani, Wilma D. J. van de Berg, Jinte Middeldorp   +4 more
wiley   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Processionary Moth Exposure in Europe: Toxic–Irritant and Immunoglobulin E‐Mediated Endotypes, Diagnosis and Management

Clinical &Experimental Allergy, EarlyView.
Most reactions are toxic–irritant, driven by epithelial injury and neuro‐inflammatory activation. IgE‐mediated allergy is less common but may cause immediate systemic reactions. Endotype differentiation guides diagnosis, risk stratification and management.
Prasad Dasari, Josefine Haas, Wolfgang Rohe, Kai Gloyna, Christoph Viebahn, Susann Forkel, Michael Szardenings, Christine Stadelmann, Michael P. Schön, Timo Buhl   +9 more
wiley   +1 more source

Nasal Obstruction Is Reduced 5–7 Years After Radiofrequency Turbinate Reduction: Results From a Retrospective Observational Cohort Study

Clinical Otolaryngology, EarlyView.
ABSTRACT Introduction Nasal obstruction, often caused by structural and inflammatory conditions, is prevalent and significantly impacts health‐related quality of life. Radiofrequency Turbinate Reduction (RFTR) is a widely employed treatment for inferior turbinate hypertrophy, yet evidence of its long‐term effectiveness remains limited. This study aimed
Veronica Ahlund, Pål Rosholm Comstedt, Maria Värendh, Pernilla Sahlstrand‐Johnson   +3 more
wiley   +1 more source

Outcomes of children and young people with cerebral palsy receiving long‐term respiratory support: A systematic review

Developmental Medicine &Child Neurology, EarlyView.
Outcomes of children with cerebral palsy receiving long‐term respiratory support. Abstract Aim To systematically review the current knowledge gap in, and impact of, long‐term respiratory support in children and young people (CYP) with cerebral palsy (CP). Method We searched six databases from inception until 30th January 2025.
Rajkumar Dhandayuthapani, Alasdair Campbell, Catherine M McDougall, Florian Gahleitner, Steve Cunningham, Don S Urquhart   +5 more
wiley   +1 more source